None (CGTX) is a publicly traded company. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist.
Analysis Summary
Balance sheet quality for CGTX: current ratio of 3.4, net cash position of $36.2M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.02 |
| Market Cap | $91M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.99 |
Price Performance
| 1 month | +4.90% |
| 3 months | -28.97% |
| Year-to-date | -23.70% |
| 1 year | -29.93% |
| 3 years | -18.25% |
52-Week Range
| 52-week High | $2.26 |
| 52-week Low | $0.55 |
| Avg Volume (90d) | 1.1M |
Related companies: AGEN · ATOS · GLSI · IRD · MCRB · SEER · SPRO
More sections of CGTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks